DiseaseSignal
Longitudinal research intelligence

What is still blocking progress?

DiseaseSignal follows the unresolved problems behind promising findings: who encounters the friction, what the evidence supports, what remains missing, and which next result would materially change confidence.

6
active bottlenecks
5
evidence stages
8
research sections
Oct 2, 2026
last evidence review
1Finding

What the primary studies actually observed.

2Friction

The unresolved problem limiting interpretation or translation.

3Missing proof

The evidence that has not yet been produced.

4Next test

The result most likely to change confidence.

How to read evidence movement

EmergingA newly supported problem worth tracking.

StrengtheningAdditional evidence reinforces the bottleneck framing.

MixedEvidence supports some parts while important conflicts or limits remain.

UnchangedNew evidence does not materially change the open problem.

WeakenedNew evidence reduces confidence that this is the central bottleneck.

These labels track an unresolved research problem. They do not score a treatment or predict benefit for an individual.

6 bottlenecks shown

Population surveillanceStrengtheningUpdated Oct 2, 2026

Can an antimicrobial-resistance estimate travel without its specimen, testing, and health-system context?

Resistance estimates may depend on care area, organism and specimen mix, sampling period, bacterial lineage and testing reliability. Hospital-wide isolate percentages do not establish comparable risks across care areas or population-wide infection rates.

Who encounters it
Microbiology laboratories, surveillance teams, infectious-disease researchers, and public-health planners.
Missing proof
Representative sampling; comparable organism, specimen and care-area denominators; patient characteristics and antibiotic-exposure data; time-resolved and lineage-adjusted comparisons; and reproducible species-appropriate testing. The European study's fosfomycin-testing limitations remain unresolved. Neither collection establishes population infection burden or patient-level treatment effects.
Next decisive test
In a prospective multicenter P. aeruginosa collection, compare care-area resistance rates after standardizing specimen type, patient characteristics, prior antibiotic exposure and bacterial lineage, with blinded repeat laboratory testing. A care-area gradient reproduced within comparable groups across hospitals would support care-area-specific estimates; disappearance after standardization would implicate sampling composition rather than a transferable care-intensity gradient.
Infection
Open evidence trail
Human diagnosticMixedUpdated Sep 13, 2026

For an unsolved rare-disease case, when does reinterpretation add more value than new sequencing?

Reanalysis can resolve previously unsolved inherited disorders, while RNA and structural assays can expose missed variants. A June 2026 hereditary-cancer cohort adds a qualification: additional candidate findings cannot count as added diagnoses without disease-specific validation.

Who encounters it
Clinical geneticists, diagnostic laboratories, rare-disease and hereditary-cancer researchers, and affected families.
Missing proof
Same-case comparisons against updated sequence reinterpretation; disease-specific validation of candidate findings; additional confirmed diagnoses attributable to each assay and variant class; complete assay coverage; standardized reanalysis intervals; broader ancestry representation; and cost and turnaround comparisons.
Next decisive test
Compare prespecified reinterpretation with added genome, RNA and structural assays in the same unresolved cases. A reproducible increase in independently validated diagnoses attributable to a particular added assay—not merely more candidates—would support escalation, with results separated by disease and variant class and accompanied by cost and turnaround measurements.
GeneticsDiscovery
Open evidence trail
Human observationalStrengtheningUpdated Aug 6, 2026

Can a screening or biomarker signal remain useful when its population, instrument, assay, clinical task, or biological source changes?

A screening measurement or biomarker can discriminate within one study without explaining where its signal comes from or whether performance will survive a new cohort, instrument, acquisition workflow, assay, threshold, or intended use.

Who encounters it
Screening researchers, biomarker developers, laboratory scientists, statisticians, and clinical-validation teams.
Missing proof
Prospective replication, prespecified thresholds, locked acquisition, specimen, preparation, timing, carrier-fraction, and culture workflows, clinically realistic disease mimics, calibration across instruments, laboratories, and populations, comparison with simpler models, and evidence connecting measured signals to their biological source.
Next decisive test
Run a prospective external validation with locked acquisition or specimen procedures, timing, carrier-fraction rules, instruments, preparation workflow, assay, clinical task, threshold, and analysis plan, then test whether calibration and biological interpretation remain stable across sites and populations.
CancerProteinsHeart & LungsDiscovery
Open evidence trail
PreclinicalStrengtheningUpdated Aug 3, 2026

Can researchers prove where a localized therapy acts—and whether that location changes its effect?

Preclinical cancer and nerve-repair strategies try to concentrate biological activity at a target site, but delivery location, material effects, exposure, target engagement, and human relevance remain separate validation problems.

Who encounters it
Translational immunologists, regenerative-medicine researchers, drug-delivery scientists, and early-phase trial designers.
Missing proof
Matched local-versus-systemic comparisons where relevant, component-removal controls for multifunctional materials, concentration and persistence measurements, direct target-engagement evidence, off-target assessment, and validation in human tissue or clinical studies.
Next decisive test
Hold the model and outcome set constant while comparing the complete localized system with its individual carrier, material, and active components, then measure local exposure, persistence, target engagement, tissue response, and safety in an appropriate translational model.
CancerPeptides
Open evidence trail
Health systemsMixedUpdated Jul 22, 2026

When a health program reaches a similar endpoint, what burden has been shifted to patients and caregivers?

A main clinical or program endpoint can look similar while treatment duration, visits, cost, transport, trust, and access change substantially.

Who encounters it
Implementation researchers, nutrition-program teams, health systems, patients, and caregivers.
Missing proof
Joint measurement of clinical outcomes, relapse, time, household cost, access, and implementation fidelity in the same populations and across different settings.
Next decisive test
Evaluate a program prospectively with a prespecified set of clinical, time, cost, access, and caregiver-burden endpoints rather than treating recovery alone as the complete outcome.
Nutrition
Open evidence trail
PreclinicalMixedUpdated Jul 22, 2026

When does a patient-derived tumor model become reliable enough to guide a clinical research decision?

Representative model collections and drug-response assays solve different validation problems; neither model fidelity nor assay agreement alone establishes clinical utility.

Who encounters it
Precision-oncology researchers, translational pharmacology teams, and trial-design groups.
Missing proof
Prospective sampling rules, representation of patients who do not generate models, reproducibility across laboratories, and blinded comparison between model predictions and patient outcomes.
Next decisive test
Pre-register a model-and-assay workflow, apply it before treatment selection, and compare its predictions with patient outcomes while accounting for model-generation failures and turnaround time.
DiscoveryCancer
Open evidence trail